H.I.G. Capital Sells Celerion to THL Partners in $1.8B CRO Deal

H.I.G. Capital, a Miami-based global alternative investment firm managing approximately $75B in capital, has completed the sale of Celerion, a clinical pharmacology-focused contract research organization (CRO), to THL Partners (Thomas H. Lee Partners) in a transaction valued at $1.8B.

The deal follows H.I.G.'s acquisition of Celerion in 2022, when the company was reportedly valued in the $600M–$700M range. Prior ownership included Court Square Capital Partners. The transaction represents a significant value creation event during H.I.G.'s ownership period.

Celerion, headquartered in Lincoln, Nebraska, was founded by Susan Thornton, Ph.D. and operates at the intersection of early-stage drug development, clinical pharmacology, and bioanalytical sciences. The company has conducted more than 6,000 clinical studies and employs more than 1,000 people across North America and Europe.

The acquisition underscores a broader trend reshaping healthcare investing: specialized pharmaceutical infrastructure is becoming increasingly valuable as drug development grows more complex, more expensive, and more dependent on expert external partners.

---

What Happened

A lot of people hear drug development and immediately picture scientists in white lab coats, billion-dollar biotech companies, and breakthrough therapies splashed across financial headlines. What they don't picture is the infrastructure. The clinical units, the data systems, the bioanalytical laboratories, and the specialized teams running first-in-human studies while investors, regulators, and pharmaceutical executives wait for answers. That's the world Celerion inhabits.

H.I.G. Capital announced the completion of Celerion's sale to THL Partners for $1.8B, closing a chapter that began when H.I.G. acquired the company in 2022. During that ownership period, Celerion expanded its position as one of the industry's leading contract research organizations focused on clinical pharmacology and early-stage development.

Founded by Susan Thornton, Ph.D., who serves as President & CEO, Celerion provides early-stage clinical research services to pharmaceutical and biotechnology companies. The company specializes in first-in-human studies, cardiac safety research, bioavailability testing, drug-drug interaction studies, and bioanalytical sciences. Those services may sound technical because they are, and increasingly, technical expertise is becoming one of the most valuable assets in healthcare.

The transaction involved leadership from both organizations, including Brian Schwartz, CEO of H.I.G. Capital, alongside Sami Mnaymneh and Tony Tamer, Co-Founders and Executive Chairmen. Deal leadership also included Michael Gallagher, Managing Director; Michael Kuritzky, Managing Director; and Matt Hankins and Rahul Vinnakota, Co-Heads of H.I.G. Advantage.

---

Why This Matters

A funny thing happens as industries mature. The spotlight drifts toward the companies building the products while the companies enabling the products quietly become indispensable. The semiconductor industry learned this lesson decades ago. Cloud computing learned it next. Pharmaceutical services are now living through the same dynamic.

Drug development has become dramatically more complicated over the past decade. Precision medicine, biologics, cell therapies, gene therapies, and increasingly sophisticated regulatory requirements have raised the bar for everyone involved. Pharmaceutical companies still discover and commercialize therapies, but more and more of the specialized work happens through external partners. That shift has elevated firms like Celerion from service providers to critical healthcare infrastructure.

The market tends to reward businesses that become difficult to replace. A specialized CRO with decades of expertise, thousands of completed studies, and deep scientific capabilities is not something competitors recreate overnight. The barriers aren't just financial. They're operational, regulatory, and reputational. Trust takes years to build, and in clinical research, trust can be worth billions.

---

Market Context

The timing of this transaction says as much about the healthcare market as it does about Celerion itself. After several difficult years for biotechnology financing, funding activity has begun stabilizing. While capital markets remain selective, investors continue to support companies advancing differentiated therapies. As biotech funding improves, demand for outsourced research services typically follows.

Contract research organizations have become increasingly important as pharmaceutical companies outsource specialized development work rather than build every capability internally. Pharmaceutical and biotechnology companies need partners capable of accelerating development timelines, managing increasingly sophisticated studies, and generating reliable data for regulatory submissions. That creates favorable conditions for specialized CROs.

Celerion's focus on clinical pharmacology places it in a particularly attractive segment of the market. Early-stage development remains one of the highest-risk phases of drug creation, and decisions made during this period can determine whether a therapy advances or disappears. The ability to generate accurate data quickly is valuable. The ability to generate accurate data repeatedly across more than 6,000 studies is something entirely different. Investors recognize the distinction.

---

Competitive Landscape

The CRO industry is crowded. The clinical pharmacology segment is not. Many organizations can offer broad clinical research capabilities, but far fewer possess the specialized expertise, infrastructure, and historical track record required to establish leadership in early-stage clinical pharmacology.

Celerion has spent years building that position. Its network includes clinical research facilities, bioanalytical laboratories, and scientific teams operating across multiple geographies. The company has conducted more than 6,000 studies and built a reputation around complex early-stage research programs.

That specialization matters because healthcare markets increasingly reward expertise over generalization. The broader pharmaceutical services sector has become one of private equity's favorite hunting grounds. When expertise becomes embedded in customer workflows, pricing power improves, retention improves, and strategic importance improves. Investors tend to notice.

---

What This Signals

The $1.8B transaction signals continued investor confidence in pharmaceutical services despite broader uncertainty across parts of the healthcare market. More importantly, it highlights a growing preference for businesses positioned behind critical industry workflows.

Infrastructure often looks boring until someone tries operating without it. Clinical pharmacology is one of those categories. The headlines usually belong to the drug developers, but the economics increasingly favor the organizations helping those developers move faster and reduce risk.

That dynamic helps explain why specialized CROs continue attracting both strategic and financial buyers. The market is sending a straightforward message: expertise remains scarce, and scarcity creates value.

---

The Bigger Industry Shift

A decade ago, many investors viewed CROs primarily as outsourced service providers. Today, the strongest firms are increasingly viewed as knowledge platforms. They accumulate data, expertise, regulatory experience, scientific talent, and operational processes that compound over time.

Healthcare infrastructure assets have become one of private equity's most active investment themes as demand for specialized scientific expertise continues to grow. That evolution changes valuation frameworks, acquisition strategies, and how investors evaluate healthcare infrastructure opportunities.

The Celerion transaction sits at the intersection of several long-term trends: increasing drug-development complexity, growing pharmaceutical outsourcing, rising demand for specialized scientific expertise, and investor appetite for businesses with durable competitive advantages. Strip away the deal mechanics and the financial engineering, and the story becomes surprisingly simple. The market continues rewarding companies that solve difficult problems repeatedly. Celerion built an entire business around doing exactly that.

---